Výsledky vyhľadávania - "Fluconazole"

  1. 1
  2. 2

    Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects Autor Tachibana, Masaya, Matsuki, Shunji, Maekawa, Yutaro, Kuroda, Kana, Shimizu, Takako, Tsutsumi, Junko, Ishizuka, Hitoshi

    ISSN: 1752-8054, 1752-8062, 1752-8062
    Vydavateľské údaje: United States John Wiley & Sons, Inc 01.11.2023
    Vydané v Clinical and translational science (01.11.2023)
    “… Itraconazole and fluconazole are antifungal medications often used as typical inhibitors of cytochrome P450 3A (CYP3A…”
    Získať plný text
    Journal Article
  3. 3

    Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects Autor Gardin, Anne, Ufer, Mike, Legangneux, Eric, Rossato, Gianluca, Jin, Yi, Su, Zhenzhong, Pal, Parasar, Li, Wenkui, Shakeri-Nejad, Kasra

    ISSN: 0312-5963, 1179-1926, 1179-1926
    Vydavateľské údaje: Cham Springer International Publishing 01.03.2019
    Vydané v Clinical pharmacokinetics (01.03.2019)
    “…). Methods Study A was an open-label, single-dose study comprising periods 1 (14 days; day 1: siponimod 4 mg) and 2 (20 days; day 1: fluconazole 200 mg twice daily; days 2–19: fluconazole 200 mg once daily; day 3: siponimod 4 mg) in healthy subjects…”
    Získať plný text
    Journal Article
  4. 4

    Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects Autor Aslanis, Vassilios, Umehara, Kenichi, Huth, Felix, Ouatas, Taoufik, Bharathy, Savita, Butler, Andrew Avigdor, Zhou, Wen, Gadbaw, Brian

    ISSN: 0344-5704, 1432-0843, 1432-0843
    Vydavateľské údaje: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2019
    Vydané v Cancer chemotherapy and pharmacology (01.10.2019)
    “…Purpose Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole…”
    Získať plný text
    Journal Article
  5. 5

    Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects Autor Dai, Yuyang, Hu, Minwan, Guo, Shaojie, Wu, Feng, Han, Ying, Ni, Siyang, Li, Shaorong, Zhu, Zhenyu, Yuan, Weilan, Zhao, Xiuli

    ISSN: 0928-0987, 1879-0720, 1879-0720
    Vydavateľské údaje: Netherlands Elsevier B.V 01.09.2025
    “… 18 Chinese healthy subjects were orally administered SHR2554 100 mg on Day 1, fluconazole 400 mg on Day 4 and 200 mg QD from Days 5 to 6…”
    Získať plný text
    Journal Article
  6. 6
  7. 7

    Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects Autor Yang, Fan, Ye, Pan‐Pan, Lv, Wen‐Shuo, Li, Li‐Ze, Zhao, Bao‐Zhong, van denAnker, John, Yang, Xin‐Mei, Song, Lin‐Lin, Yang, Xiao‐Ran, Zheng, Yi, Ke, Bo‐Wen, Zhao, Wei

    ISSN: 0091-2700, 1552-4604, 1552-4604
    Vydavateľské údaje: England Wiley Subscription Services, Inc 01.11.2025
    Vydané v Journal of clinical pharmacology (01.11.2025)
    “…‐26 in 68 healthy subjects across three sequences, evaluating interactions with rifampin (CYP2C19/3A4 inducer), fluconazole…”
    Získať plný text
    Journal Article
  8. 8
  9. 9

    A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS Autor Vazquez, Jose A, Skiest, Daniel J, Nieto, Leopoldo, Northland, Rebeca, Sanne, Ian, Gogate, Jagadish, Greaves, Wayne, Isaacs, Randi

    ISSN: 1537-6591, 1537-6591
    Vydavateľské údaje: United States 15.04.2006
    Vydané v Clinical infectious diseases (15.04.2006)
    “… (including fluconazole-resistant strains). This multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole…”
    Zistit podrobnosti o prístupe
    Journal Article
  10. 10

    Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial Autor Prates, Fernanda V de O, Dourado, Mayra E F, Silva, Silvana C, Schriefer, Albert, Guimarães, Luiz H, Brito, Maria das Graças O, Almeida, Juliana, Carvalho, Edgar M, Machado, Paulo R L

    ISSN: 1537-6591, 1537-6591
    Vydavateľské údaje: United States 01.01.2017
    Vydané v Clinical infectious diseases (01.01.2017)
    “…  A total of 53 subjects were included in the trial; 26 were treated with Sb , and 27 with fluconazole…”
    Zistit podrobnosti o prístupe
    Journal Article
  11. 11

    Brown locusts, Locustana pardalina, host fluconazole-resistant Candidozyma (Candida) auris, closely related to Clade III clinical strains Autor Ogundeji, Adepemi, Bello-Akinosho, Maryam, Swart, Vaughn, Featherston, Jonathan, Cason, Errol D, Bolsenbroek, Armand, Beneke, Carel, Musoke, Jolly, Baker, Tyla, Ismail, Arshad, Sebolai, Olihile, Albertyn, Jacobus, Pohl, Carolina

    ISSN: 1369-3786, 1460-2709, 1460-2709
    Vydavateľské údaje: England Oxford University Press 05.08.2025
    Vydané v Medical mycology (Oxford) (05.08.2025)
    “…) auris is a subject of speculation, with hypotheses including avian species and marine environments…”
    Získať plný text
    Journal Article
  12. 12

    An open label, single arm, pilot study to evaluate the safety, tolerability, and efficacy of daily fluconazole 150 mg in subjects suffering from Tinea cruris and Tinea corporis [version 1; peer review: awaiting peer review] Autor Saple, Dattatray Gopal, Save, Sushrut, Kumar, Devesh, Sood, Suneet

    ISSN: 2046-1402, 2046-1402
    Vydavateľské údaje: 2022
    Vydané v F1000 research (2022)
    “…Background: Dermatophytes are the most common superficial fungal infections worldwide and are treated with prescribed regimens of terbinafine and itraconazole, or with weekly doses of fluconazole…”
    Získať plný text
    Journal Article
  13. 13

    An open label, single arm, pilot study to evaluate the safety, tolerability, and efficacy of daily fluconazole 150 mg in subjects suffering from Tinea cruris and Tinea corporis [version 2; peer review: 1 approved with reservations, 1 not approved] Autor Saple, Dattatray Gopal, Save, Sushrut, Kumar, Devesh, Sood, Suneet

    ISSN: 2046-1402, 2046-1402
    Vydavateľské údaje: 2022
    Vydané v F1000 research (2022)
    “…Background Dermatophytes are the most common superficial fungal infections worldwide and are treated with prescribed regimens of terbinafine and itraconazole, or with weekly doses of fluconazole…”
    Získať plný text
    Journal Article
  14. 14

    Cytochrome P450 epoxygenase dependence of opioid analgesia: fluconazole does not interfere with remifentanil-mediated analgesia in human subjects Autor Oertel, B G, Vermehren, J, Huynh, T T, Doehring, A, Ferreiros, N, Zimmermann, M, Geisslinger, G, Lötsch, J

    ISSN: 1532-6535, 1532-6535
    Vydavateľské údaje: United States 01.12.2014
    “… This suggestion was predicated on observations of highly attenuated morphine antinociception in rodents after intracerebroventricular injection of fluconazole or carrying a neuron-specific deletion…”
    Zistit podrobnosti o prístupe
    Journal Article
  15. 15

    Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults Autor Chen, Lu, van Rhee, Koen P, Wasmann, Roeland E, Krekels, Elke H J, Wiezer, Marinus J, van Dongen, Eric P A, Verweij, Paul E, van der Linden, Paul D, Brüggemann, Roger J, Knibbe, Catherijne A J

    ISSN: 1460-2091, 1460-2091
    Vydavateľské údaje: England 28.07.2022
    Vydané v Journal of antimicrobial chemotherapy (28.07.2022)
    “…Fluconazole is commonly used to treat or prevent fungal infections. It is typically used orally but in critical situations, IV administration is needed…”
    Zistit podrobnosti o prístupe
    Journal Article
  16. 16

    Serum 4β-hydroxycholesterol increases during fluconazole treatment Autor Lütjohann, Dieter, Stellaard, Frans, Kerksiek, Anja, Lötsch, Jörn, Oertel, Bruno G

    ISSN: 0031-6970, 1432-1041, 1432-1041
    Vydavateľské údaje: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2021
    “…-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum…”
    Získať plný text
    Journal Article
  17. 17
  18. 18

    Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects Autor Malhotra, Bimal, Dickins, Maurice, Alvey, Christine, Jumadilova, Zhanna, Li, Xiaoxi, Duczynski, Gregory, Gandelman, Kuan

    ISSN: 0306-5251, 1365-2125, 1365-2125
    Vydavateľské údaje: Oxford, UK Blackwell Publishing Ltd 01.08.2011
    “…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Available data suggest that fesoterodine dosage should not exceed 4…”
    Získať plný text
    Journal Article
  19. 19

    Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes Autor Cho, Chang-Keun, Kang, Pureum, Jang, Choon-Gon, Lee, Yun Jeong, Bae, Jung-Woo, Choi, Chang-Ik, Lee, Seok-Yong

    ISSN: 0253-6269, 1976-3786, 1976-3786
    Vydavateľské údaje: Seoul Pharmaceutical Society of Korea 01.03.2025
    Vydané v Archives of pharmacal research (01.03.2025)
    “…This study aimed to investigate the effects of fluconazole, a moderate inhibitor of CYP2C9 and CYP3A4, on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes…”
    Získať plný text
    Journal Article
  20. 20

    Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers Autor Chen, Xue, Yang, Feng, Zhao, Jiao, Tang, Qi, Heng, Jianfu, Deng, Jun, Zhang, Jin, Chen, Yong, Li, Kunyan, Wang, Jing

    ISSN: 0344-5704, 1432-0843, 1432-0843
    Vydavateľské údaje: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2022
    Vydané v Cancer chemotherapy and pharmacology (01.01.2022)
    “… We evaluated the pharmacokinetics and tolerability of fuzuloparib by fluconazole, which is a broad antifungal agent and a moderate inhibitor of CYP3A4…”
    Získať plný text
    Journal Article